Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?

Canopy Growth is approaching positive adjusted EBITDA with Q1 fiscal 2027 revenue up 13% year-over-year to $57.4 million, narrowing adjusted EBITDA losses to $2.3 million from $5.7 million. The MTL Cannabis acquisition is driving growth across Canadian medical, adult-use, and international markets, with expected $7.2 million in annual cost savings. However, free cash flow deteriorated to a $18.5 million outflow, raising concerns about cash generation despite an encouraging balance sheet with $241.4 million in cash.

09/30/2026, 11:23 AM • The Motley Fool

Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

Tilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.

09/15/2026, 10:39 AM • The Motley Fool

Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted. Here's Why.

Canopy Growth reported 13% year-over-year revenue growth to $58.9 million in Q1 fiscal 2027, with improved gross margins and narrowed EBITDA losses. However, the stock barely moved because the company remains unprofitable, continues burning cash ($18.6M free cash outflow), and some growth came from acquisitions rather than organic expansion. Investors are skeptical after years of failed turnaround promises and want proof of sustainable profitability before rewarding the stock.

09/07/2026, 7:20 AM • The Motley Fool

Should You Buy Canopy Growth Stock on the Rebound?

Canopy Growth showed strong Q1 fiscal 2027 results with 13% revenue growth across all business divisions, improved gross margins, and significantly reduced losses. However, the company remains a penny stock with over 400% share dilution in three years. While the business turnaround is promising, the article recommends most investors monitor rather than buy, citing the sector's history of underperformance and the need to see sustained improvement before investing.

09/05/2026, 7:15 AM • The Motley Fool

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

The cannabis sector is undergoing consolidation as weaker players exit and stronger companies acquire competitors. Curaleaf has made an unsolicited $4 per share bid for Aurora Cannabis. The article identifies Canopy Growth and Tilray Brands as the biggest potential winners in this consolidation trend, with Canopy benefiting from its balance sheet reset and Tilray diversifying beyond marijuana into alcohol and consumer brands.

08/21/2026, 8:15 AM • The Motley Fool

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

Curaleaf launched an unsolicited $272 million bid to acquire Aurora Cannabis at $4 per share, signaling renewed consolidation in the cannabis industry. The move raises questions about whether Canopy Growth could become the next acquisition target. While Canopy has valuable global medical cannabis assets and established brands, its complex corporate structure and ongoing turnaround make it a less obvious fit for potential acquirers.

08/16/2026, 12:30 AM • The Motley Fool

Thinking About Buying Canopy Growth? You May Want to Wait for This 1 Thing to Happen First.

The key catalyst for Canopy Growth stock is the DEA's decision on rescheduling cannabis to Schedule III, which could happen soon given President Trump's executive order. While rescheduling would benefit the company by allowing consolidation of its U.S. affiliate and eliminating section 280E tax deductions, the article advises waiting rather than buying ahead of the announcement, as past regulatory news has caused temporary surges followed by selloffs. Long-term investors should view cannabis stocks as a legalization bet, not a short-term binary trade.

07/25/2026, 10:30 AM • The Motley Fool

President Trump's Major Marijuana Move: What It Means for Canopy Growth, Green Thumb, and Tilray

President Trump's executive order to reschedule medical marijuana from Schedule I to Schedule III provides limited benefits to major cannabis companies. While the rescheduling eliminates IRS Section 280E tax restrictions for medical marijuana businesses, it only applies to medical products, not the larger recreational market. Canopy Growth, Tilray, and Green Thumb Industries face minimal direct impact due to their business structures and market focus, though the change creates new regulatory compliance burdens.

07/17/2026, 5:30 AM • The Motley Fool

Canopy Growth's Medical Marijuana Sales Are Soaring. Is the Beaten-Down Stock Ready to Rebound?

Canopy Growth reported strong 27% growth in its medical marijuana division in Q4 fiscal 2026, but the rest of the business showed weakness. The recreational marijuana segment grew only 1% in Q4, international cannabis sales fell 7% year-over-year, and the Storz & Bickel vaporizer business declined 14%. The company continues to report negative earnings and faces declining gross margins, making it a risky investment despite one strong division.

06/28/2026, 9:15 AM • The Motley Fool

Trulieve Makes History As First US Cannabis Stock On NYSE

Trulieve Cannabis Corp. became the first U.S. cannabis company to list on a major U.S. stock exchange (NYSE: TRLV), enabled by the Trump administration's reclassification of cannabis to Schedule III. The company separated its medical and adult-use operations to meet exchange requirements. Competitors like Curaleaf and Verano are preparing for similar uplistings, while Canadian producers remain on Nasdaq. The listing has energized the cannabis sector.

06/10/2026, 5:25 PM • Benzinga

The Market Overreacted to the DEA's Marijuana Rescheduling -- Here's What It Means for Canopy Growth Stock Now

The DEA's rescheduling of marijuana from Schedule I to Schedule III in April 2026 was initially seen as historic but has had muted impact. The rescheduling only applies to medical marijuana and provides limited benefits like IRS Section 280E relief. Canopy Growth, a major Canadian cannabis company, cannot fully capitalize on these changes due to its non-controlling interest in its U.S. affiliate Canopy USA, whose results remain unconsolidated. The analyst concludes the rescheduling won't materially affect Canopy Growth soon and does not recommend the stock as a buy.

06/02/2026, 1:15 AM • The Motley Fool

Canopy Growth Is Restating Two Years of Financials Before June 15 Earnings -- Here's What CGC Investors Need to Know Right Now

Canopy Growth announced it will restate financial results for two years due to a technical accounting error involving share-settled warrants that should have been classified as liabilities rather than equity. The company states the restatement won't impact revenue, operating income, cash flows, or key performance metrics. However, the stock remains a risky penny stock in a struggling marijuana sector facing intense competition and illicit market pressures. Most investors should avoid the stock until it achieves sustainable profitability and the restatement is complete.

05/22/2026, 11:15 PM • The Motley Fool

Is Canopy Growth Stock Finally Setting Up for a Real Turnaround?

Canopy Growth has reduced debt and accumulated cash, but achieved this through significant share dilution. The company remains unprofitable even on an EBITDA basis. However, the recent acquisition of MTL Cannabis could create cost synergies and improve profitability. Investors are advised to wait for the May 29 earnings release before making investment decisions.

05/15/2026, 12:30 PM • The Motley Fool

Canopy Growth Is One of the Market's Most Polarizing Stocks: 3 Scenarios for the Next 12 Months

Canopy Growth shows early signs of stabilization after years of losses and restructuring, with narrowing EBITDA losses and 8% revenue growth in Canadian adult-use cannabis. However, investors remain divided on whether this represents a genuine turnaround or merely an extension of decline, given persistent industry oversupply, pricing pressure, and the company's continued unprofitability.

05/14/2026, 6:15 AM • The Motley Fool

New Cannabis Rules Just Created Winners and Losers: What the Split Schedule Means for Medical Operators and MSOs

New federal cannabis tax rules are reshaping the industry with a split schedule that benefits medical-only operators while challenging multi-state operators. Medical-only companies like Trulieve could see faster margin and cash-flow improvements, while multi-state cannabis companies may face new tax-allocation hurdles that pressure near-term earnings.

04/30/2026, 4:20 PM • The Motley Fool